CervoMed completes enrollment in phase 2a nfvPPA trial
AI Summary
CervoMed completed enrollment in its phase 2a clinical trial for non-fluent variant primary progressive aphasia (nfvPPA). This progress marks an important milestone in developing treatments for neurodegenerative conditions.